Tahir Misbah's Form 4 filing
IGM Biosciences, Inc. (IGMS) · filed Nov 29, 2023
- Accession no.
- 0001209191-23-056944
- Filed
- Nov 29, 2023
- Trade date
- Nov 15-27, 2023
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $6.77K. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tahir MisbahCIK 0001787359 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 15, 2023 | Common Stock | AGrant or awardAcquired | +234 | $11.71 | +$2,740.14 | 50,945 | Direct | |
| Nov 27, 2023 | Common Stock | SSaleDisposed | −1,337 | $5.06F3 | −$6,765.22 | 49,608 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $4.96 to $5.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.